Pfizer: Eczema trials

The registry lists 25 Eczema studies with Pfizer as lead sponsor. 6 are open to participants now and 12 have results posted.

Phase 1 1Phase 2 7Phase 3 14No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of AgeNot yet recruitingNCT07823595Phase 3
• A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe EczemaRecruitingNCT07783425Phase 3
• A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe EczemaRecruitingNCT07765888Phase 3
• A Study to Learn About Study Medicine Called PF-08049820 in People With EczemaRecruitingNCT07216027Phase 2
• A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe EczemaRecruitingNCT06807281Phase 3
• A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.RecruitingNCT05689151
• A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by InjectionTerminatedNCT05732454Phase 2/3Results posted
• A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.CompletedNCT05375955Phase 2Results posted
• A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic DermatitisTerminatedNCT04498403Phase 3Results posted
• Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical TherapyCompletedNCT04345367Phase 3Results posted
• A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic DermatitisCompletedNCT04040192Phase 3Results posted
• Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic DermatitisCompletedNCT03915496Phase 2Results posted
• Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical TherapyCompletedNCT03720470Phase 3Results posted
• Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring SubjectsCompletedNCT03627767Phase 3Results posted
• Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic DermatitisCompletedNCT03575871Phase 3Results posted
• Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic DermatitisCompletedNCT03349060Phase 3Results posted
• Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic DermatitisCompletedNCT03233529Phase 2Results posted
• Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)CompletedNCT02001181Phase 2Results posted
• A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe EczemaActive, not recruitingNCT06807268Phase 3
• Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)CompletedNCT06353087
• A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisActive, not recruitingNCT05995964Phase 2
• A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.Active, not recruitingNCT05387980
• Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic DermatitisNo longer availableNCT04564755
• A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy ParticipantsCompletedNCT04135560Phase 1
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic DermatitisCompletedNCT03422822Phase 3